Alnylam Pharmaceuticals – Hereditary amyloidosis

Submitted By:

Published Date:

January 25, 2020

<p>The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).</p>

Rare Disease:

Hereditary amyloidosis